- Abdul Latif Jameel Health acquires a majority stake in Genpharm, signalling a commitment to patient-centric healthcare in the Middle East, North Africa, and Turkey.
- Genpharm, a leader in rare diseases and gene therapy, boasts twelve years of experience, market access, and impactful solutions for genetic diseases and speciality therapeutics.
- The collaboration aims to redefine healthcare standards, drive innovation, and ensure accessible cutting-edge medical care for the Global South.
Abdul Latif Jameel Health, the healthcare arm of the internationally acclaimed Abdul Latif Jameel for nearly eight decades, has announced its strategic acquisition of a majority stake in Genpharm. This collaboration signifies a significant milestone for both entities reflecting a powerful commitment to patient-centric healthcare, inclusivity, and expediting access to cutting-edge medical care in the Middle East, North Africa, and Turkey.
Genpharm, celebrating its 12th anniversary, stands tall as the leading partner for rare diseases, boasting extensive market access across the region. Founded in 2012, the company has consistently demonstrated an unwavering commitment to evidence-based medicine and the highest ethical standards. It proudly holds the distinction of being among the first regional companies to introduce expertise in gene therapy, making it a trailblazer in the field.
As the preferred commercial partner for a diverse range of rare genetic diseases, orphan drugs, and speciality therapeutics, Genpharm’s impact is profound. Managed by seasoned senior pharmaceutical industry executives with a wealth of experience in the region and multinational organizations, Genpharm also provides strategic advice to partners on disease areas, product launches, and go-to-market strategies.
Karim Smaira, Chief Executive Officer, and Kamel Ghammachi, Chief Commercial Officer, co-founders of Genpharm, shared their vision in a joint statement, “Establishing Genpharm in 2012 was driven by the desire to create a legacy we could proudly share with our children. Recognizing the substantial gap in meeting rare disease patients’ needs in the Middle East, our values – always putting patients first, being passionate about what we do, and delivering on our promises – align seamlessly with Abdul Latif Jameel Health’s mission.”
The partnership with Abdul Latif Jameel, one of the region’s most respected businesses, holds immense promise. “Joining an organization backed by Abdul Latif Jameel means we can do more, reach more, and help more,” the co-founders emphasized. They expressed anticipation for the collaboration, highlighting the positive impact on their employees committed to bringing cures to patients in the MENA region.
Akram Bouchenaki, CEO of Abdul Latif Jameel Health, expressed admiration for Genpharm’s achievements in the region’s healthcare industry. “In the last decade, Karim and Kamel have led their team to focus on delivering niche therapeutics for rare diseases, emerging as pioneers in gene therapy,” he remarked. The innovative drive and accomplishments of Genpharm align seamlessly with Abdul Latif Jameel Health’s mission to employ technology and innovative approaches for accessible medical care.
The strategic acquisition maintains Genpharm’s existing executive structure, with Karim Smaira and Kamel Ghammachi retaining their roles as CEO and Chairman. Akram Bouchenaki will transition to a new role within the Genpharm Board of Directors, adding strength to the company’s strategic governance.
Abdul Latif Jameel Health, established in 2020 in response to global healthcare disparities, focuses on accelerating access to modern medical care and driving healthcare inclusion across the Global South. Reflecting the Jameel Family’s commitment to innovating for a better future, Abdul Latif Jameel Health operates in the commercial environment to address real-world needs today, paving the way for a more beautiful tomorrow. The organization collaborates with partners worldwide, opening and expanding new markets for the distribution of existing solutions and investing in the future of MedTech.
In this dynamic partnership, Abdul Latif Jameel Health’s acquisition of Genpharm signifies a profound commitment to revolutionizing healthcare solutions, driving innovation, and creating a lasting legacy for the future. Together, these two powerhouses are set to redefine healthcare standards across the Middle East, North Africa, and Turkey, ensuring that cutting-edge medical care reaches those who need it most.
The alliance between Abdul Latif Jameel Health and Genpharm represents not just a business venture but a transformative journey toward a healthier and more inclusive future for the Global South.
About Abdul Latif Jameel Health
Abdul Latif Jameel Health, backed by the esteemed Abdul Latif Jameel conglomerate, boasts a rich legacy spanning eight decades. It has become a trusted beacon of innovation in healthcare. With a presence in 34 countries across six continents, their extensive reach and diversified expertise uniquely position them to drive breakthroughs and seize opportunities in the ever-evolving healthcare landscape. Abdul Latif Jameel Health is a committed partner, dedicated to advancing major innovations and contributing to the global evolution of healthcare.
Follow us on Instagram, LinkedIn, and Twitter for startup & business news and inspiring stories of MENA businesses, entrepreneurs, startups, innovators, investors, and change-makers.
To report any issue or error in the story, please email us editor [at] rasmal [dot] com.
Last Updated on January 30, 2024 by Safiya K
